<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431689</url>
  </required_header>
  <id_info>
    <org_study_id>32015</org_study_id>
    <nct_id>NCT02431689</nct_id>
  </id_info>
  <brief_title>Delayed Embryo Transfer in Poor Responders</brief_title>
  <official_title>Antagonist and Short Protocols in Invitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) Cycles With Delayed Embryo Transfer in Poor Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nile Ivf Center, Cairo, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kamal Shaeer center of infertility</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poor ovarian response indicates inadequate ovarian response to ovarian stimulation. In the
      current study the investigators will attempt to compare antagonist and short protocols
      regarding oocyte as well as embryo quantity and quality. Frozen embryo transfer will be
      performed in order to abolish iatrogenic effect of stimulation drugs on implantation. Still
      implantation and pregnancy rates are considered secondary outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Metaphase II (MII) oocytes</measure>
    <time_frame>9-14 days from stimulation</time_frame>
    <description>Number of MII oocytes collected from each patient on the day of ovum pickup (OPU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of good embryos</measure>
    <time_frame>3-5 days after ovum pickup</time_frame>
    <description>the number of good quality embryos obtained from each patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chemical pregnancy rate</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>positive serum Beta HCG 14 days after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>the detection of intrauterine gestational sac with positive pulsations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>the ratio between the number of embryos transferred and the number of sacs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy loss in the first 12 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy ongoing beyond 12 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>9 months</time_frame>
    <description>Pregnancy ending with a live birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVF/ICSI</intervention_name>
    <description>controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.</description>
    <arm_group_label>Antagonist</arm_group_label>
    <arm_group_label>Short</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient selection is based on the ESHRE consensus group 2011 definition of poor
             ovarian response (POR) (Bologna criteria):

          -  At least two of the following three features must be present:

               1. Advanced maternal age (≥40 years) or any other risk factor for POR;

               2. A previous POR (≤3 oocytes with a conventional stimulation protocol);

               3. An abnormal ovarian reserve test (i.e. Antral follicle count (AFC) &lt;5-7 follicles
                  or Antimullerian hormone (AMH) &lt;0.5-1.1 ng/ml).

        Two episodes of POR after maximal stimulation are sufficient to define a patient as poor
        responder in the absence of advanced maternal age or abnormal Ovarian reserve test (ORT).
        By definition, the term POR refers to the ovarian response and, therefore, one stimulated
        cycle is considered essential for the diagnosis of POR. However, patients over 40 years of
        age with an abnormal ORT may be classified as poor responders since both advanced age and
        an abnormal ORT may indicate reduced ovarian reserve and act as a surrogate of ovarian
        stimulation cycle. In this case, the patients should be more properly defined as expected
        PORs.

        Exclusion Criteria:

          -  Women with endometriosis, endocrinal problems, uterine abnormalities as well as male
             azospermia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iman K Shaeer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)</name>
      <address>
        <city>Cairo</city>
        <zip>12311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamal Shaeer center of infertility</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nile IVF center</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>May 12, 2018</last_update_submitted>
  <last_update_submitted_qc>May 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Yasmin Ahmed Bassiouny</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

